TheTechno Optimist.

LanifibranorInventiva—Inventiva: last NATiV3 patient completes 72 weeks; lanifibranor topline on track for Q4 2026

Inventiva

Lanifibranor, pan-PPAR pill, MASH

FRpublicinventivapharma.com (opens inventivapharma.com)Checked 11 Oct

The brief

Analyst view

NATiV3: 1,009-patient phase 3, last 72-week visit done Sep 2026; topline Q4 2026.
If positive: US filing H1 2027 for accelerated approval, possible 2028 launch.
€233.9M cash at 30 Jun 2026; runway into Q2 2027 (early 2028 with conditional debt).